The Pleiotropic Effects of Atorvastatin When Combined With Common Antihypertenisve Medications.
- Registration Number
- NCT00656331
- Lead Sponsor
- University of New Mexico
- Brief Summary
The purpose of this study is to compare the effects of the cholesterol medication taken with each blood pressure medication alone on heart disease risk factors including blood pressure, cholesterol, inflammation, blood sugar control, blood vessal function, and other heart disease risk factors.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- mild hypertension and high cholesterol
Exclusion Criteria
- diabetes and heart disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Amlodipine and Hydrocholorothiazide Amlodipine 2 Amlodipine and Hydrocholorothiazide HCTZ
- Primary Outcome Measures
Name Time Method PAI-1 study completion
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Atorvastatin's pleiotropic effects when combined with amlodipine or hydrochlorothiazide in hypertension management?
How does the combination of Atorvastatin with amlodipine compare to its combination with hydrochlorothiazide in modulating endothelial function and inflammatory biomarkers in hypertensive patients?
Which biomarkers are associated with differential response to Atorvastatin-amlodipine versus Atorvastatin-hydrochlorothiazide combinations in managing cardiovascular risk factors?
What are the potential adverse event profiles and management strategies for Atorvastatin combined with calcium channel blockers or thiazide diuretics in hypertension treatment?
How do the pleiotropic effects of Atorvastatin in NCT00656331 compare to other statin-based combination therapies for metabolic syndrome and atherosclerosis?
Trial Locations
- Locations (1)
UNMHSC
🇺🇸Albuquerque, New Mexico, United States
UNMHSC🇺🇸Albuquerque, New Mexico, United States